Event info
Date:21 Jan, 2026
Time:08:30-11:00
Venue:Medicon Valley Alliance, Copenhagen

SIGN UP

Contact person
Mia Ritterband-Rosenbaum

Mia Ritterband-Rosenbaum

Event Manager & PA to CEO

mrr@mva.org

+45 21 63 38 88

From Discovery to Therapeutics: Advancing Treatment Through Peptides and Oligonucleotides

Join us for a morning where biological insight meets therapeutic ambition, and the path from concept to clinic comes into sharp focus. Medicon Valley Alliance and Syngene International would like to welcome you to a Good Morning Meeting 21th of January 2026.

Engage with leaders shaping tomorrow’s treatments, and gain perspectives that strengthen scientific collaboration and innovation.

Date: Wednesday, 21 January 2026
Time: 8:30 – 11:00
Venue: Medicon Valley Alliance, Arne Jacobsens Allé 15, 2300 Copenhagen S, Denmark – Hub 2

 

SIGN UP

Program

8:30 Networking, registration and light breakfast
9:00 Welcome and introduction to Medicon Valley Alliance
David Munis Zepernick, Director, Member Engagement & Communication, Medicon Valley Alliance
9:05 Welcome and introduction to Syngene
Mattias Nyström, Senior Director Business Development, Northern Europe, Syngene International Ltd.
9:15 Making the Untreatable Treatable: Translating Biology into Medicine, Focus and build excellence in the translation of biological insight and concept into innovative medical treatment and thereby improve the likelihood to treat untreatable disorder
Allan Wehnert, CEO & Founder, Orocidin A/S
9:45 Follow the Molecule: from Discovery to Commercialization
Stephane Lefevre, Director Business development, Peptides and Oligonucleotides, Syngene International Ltd.
10:00 Networking
11:00 End of Good Morning Meeting

 

Speakers​​

​​​

Allan Wehnert, CEO & Founder, Orocidin A/S
 
Stephane Lefevre, Director Business development, Peptides and Oligonucleotides, Syngene International Ltd.

Stéphane Lefevre is Global Strategic Lead – TIDES at Syngene International, responsible for driving global growth in oligonucleotide and peptide businesses. He collaborates with cross-functional teams to deliver integrated solutions from discovery through commercialization. Stéphane holds a Ph.D. in Life Sciences from Bordeaux University and completed two postdoctoral fellowships funded by Cancer Research UK before transitioning to the pharmaceutical industry in Switzerland. At Bachem, he spent five years in commercial and leadership roles, managing key accounts and leading business development teams. Passionate about collaboration and innovation, Stéphane enjoys hiking, cycling, and skiing, and is driven by continuous learning and a commitment to excellence.

 

​​

Organized by In collaboration with